2002 - Karo Bio

Promising compounds were generated in the collaboration with Bristol-Myers Squibb for treatment of obesity. The first compound in clinical development was abandoned due to potential toxic effects. The collaboration was extended for an additional six months until March 31, 2003.
Project goals in the Aventis Biokey® collaboration were achieved. Milestone payments received.
41 new patents were granted during the year. Most significant were US patents for compounds targeting glucocorticoid and thyroid hormone receptors for treatment of metabolic disorders.